The landscape in various lymphoma subsets has changed in ways many may not have expected a decade or so ago and will continue to evolve further as new treatments against novel targets start to show their true colours.

Let’s not forget the original emergence of BTK inhibition caught a lot of people by surprise, so if we think about the next five years ahead, where might some of the next innovations come from and how might different segments potentially look in terms of new regimens?

In our latest expert interview, we take a look at an emerging pipeline in this hematologic niche and discuss where some of the early stage data might lead us to going forward.

Of course the caveat in oncology is most products will not actually make it to phase 3 development or even succeed there, yet the big attraction is in exploring emerging products to see where the trends might lead, because you never know which ones will shine down the road…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by